Brief: Combigene Signs Agreement To Evaluate Gene Therapy Candidate

Larkberget AB

25/01/2022 10:01

Jan 25 (Reuters) - Combigene AB  COMBI.ST :
    * COMBIGENE SIGNS AGREEMENT TO EVALUATE THE LEADING GENE
THERAPY
CANDIDATE WITHIN THE LIPODYSTROPHY PROJECT CGT2
    * AGREEMENT COMPRISES ONE PILOT STUDY AND ONE MAIN STUDY IN
WHICH
COMBIGENE'S MOST PROMISING GENE THERAPY CANDIDATE WITHIN
LIPODYSTROPHY PROJECT CGT2 WILL BE EVALUATED

Source text for Eikon:  ID:nMFN6rbhRG 
Further company coverage:  COMBI.ST 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))